HOXA9 is required for survival in human MLL-rearranged acute leukemias

Blood

Volumn 113, Issue 11, 2009, Pages 2375-2385

  Faber, Joerg ^a   Krivtsov, Andrei V ^a   Stubbs, Matthew C ^a   Wright, Renee ^b   Davis, Tina N ^b   Van Heuvel Eibrink, Marry Den ^c   Zwaan, Christian M ^c   Kung, Andrew L ^a,b   Armstrong, Scott A ^a,b,d,e  

^a Children's Hospital   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d HARVARD STEM CELL INSTITUTE   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOX PROTEIN; HOXA9 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR MEF2C; TRANSCRIPTION FACTOR MEIS1; TRANSCRIPTION FACTOR PBX3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMOSOME REARRANGEMENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GERM LINE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; STEM CELL; TRANSPLANTATION;

EID: 64049095814     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-113597     Document Type: Article

References (66)

1. Chen CS, Hilden JM, Frestedt J, et al. The chromosome 4q21 gene (AF-4/FEL) is widely expressed in normal tissues and shows breakpoint diversity in t(4;11)(q21;q23) acute leukemia. Blood. 1993;82:1080-1085.
2. Janssen JW, Ludwig WD, Borkhardt A, et al. Pre- pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission. Blood. 1994;84:3835-3842.
3. Kaneko Y, Shikano T, Maseki N, et al. Clinical characteristics of infant acute leukemia with or without 11q23 translocations. Leukemia. 1988;2: 672-676.
4. Borkhardt A, Wuchter C, Viehmann S, et al. Infant acute lymphoblastic leukemia: combined cytoge- netic, immunophenotypical and molecular analysis of 77 cases. Leukemia. 2002;16:1685-1690.
5. Pui CH, Behm FG, Raimondi SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med. 1989;321:136-142.
6. Super HJ, McCabe NR, Thirman MJ, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993;82:3705-3711.
7. OhshimaA, Miura I, Chubachi A, et al. 11q23 aberration is an additional chromosomal change in de novo acute leukemia after treatment with eto- poside and mitoxantrone. Am J Hematol. 1996; 53:264-266.
8. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001;20:5695-5707.
9. Chen CS, Sorensen PH, Domer PH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood. 1993;81:2386- 2393.
10. Heerema NA, Arthur DC, Sather H, et al. Cytoge- netic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: impact of the 11q23 breakpoint on outcome: a report of the Childrens Cancer Group. Blood. 1994;83:2274-2284.
11. Rubnitz JE, Link MP, Shuster JJ, et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1994;84:570-573.
12. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359:1909-1915.
13. Pui CH, Campana D. Age-related differences in leukemia biology and prognosis: the paradigm of MLL-AF4-positive acute lymphoblastic leukemia. Leukemia. 2007;21:593-594.
14. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41-47.
15. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133-143.
16. Ferrando AA, Armstrong SA, Neuberg DS, et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003;102:262-268.
17. Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14:355-368.
18. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823-833.
19. Cheung N, Chan LC, Thompson A, Cleary ML, So CW. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol. 2007;9:1208-1215.
20. Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14:355-368.
21. Rozovskaia T, Feinstein E, Mor O, et al. Upregu- lation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4:11) abnormality. Onco-gene. 2001;20:874-878.
22. Drabkin HA, Parsy C, Ferguson K, et al. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia. 2002;16:186-195.
23. Lavau C, Luo RT, Du C, Thirman MJ. Retrovirus- mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc Natl Acad Sci USA. 2000;97:10984-10989.
24. Kumar AR, Hudson WA, Chen W, Nishiuchi R, Yao Q, Kersey JH. Hoxa9 influences the pheno- type but not the incidence of Mll-AF9 fusion gene leukemia. Blood. 2004;103:1823-1828.
25. So CW, Karsunky H, Passegue E, Cozzio A, Weissman IL, Cleary ML. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell. 2003;3:161-171.
26. Zeisig BB, Milne T, Garcia-Cuellar MP, et al. Hoxa9 and Meis1 are key targets for MLL-ENL- mediated cellular immortalization. Mol Cell Biol.2004;24:617-628.
27. Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17:2298-2307.
28. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818-822.
29. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell.2006;10:257-268.
30. Milne TA, Briggs SD, Brock HW, et al. MLL tar- gets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10:1107- 1117.
31. Nakamura T, Mori T, Tada S, et al. ALL-1 is a his- tone methyltransferase that assembles a super- complex of proteins involved in transcriptional regulation. Mol Cell. 2002;10:1119-1128.
32. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 2005;65:11367- 11374.
33. Guenther MG, Jenner RG, Chevalier B, et al. Global and Hox-specific roles for the MLL1 meth- yltransferase. Proc Natl Acad Sci U S A. 2005; 102:8603-8608.
34. Borrow J, Shearman AM, Stanton VP Jr, et al. The t(7;11)(p15;p15) translocation in acute my- eloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet. 1996;12:159-167.
35. Nakamura T, Largaespada DA, Lee MP, et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15; p15) in human myeloid leukaemia. Nat Genet. 1996;12:154-158.
36. Calvo KR, Sykes DB, Pasillas MP, Kamps MP. Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral coexpres- sion of Hoxa9 and Meis1. Oncogene. 2002;21: 4247-4256.
37. Kroon E, Thorsteinsdottir U, Mayotte N, NakamuraT, Sauvageau G. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J. 2001;20:350-361.
38. 38.Buske C, Feuring-Buske M, Abramovich C, et al. Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood. 2002;100:862-868.
39. Nakamura T, Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet. 1996;12:149-153.
40. Sauvageau G, Thorsteinsdottir U, Eaves CJ, et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev. 1995;9:1753-1765.
41. Thorsteinsdottir U, Mamo A, Kroon E, et al. Over- expression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood. 2002;99:121-129.
42. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21:224-234.
43. Daga A, Podesta M, Capra MC, Piaggio G, Frassoni F, Corte G. The retroviral transduction of HOXC4 into human CD34(+) cells induces an in vitro expansion of clonogenic and early progenitors. Exp Hematol. 2000;28:569-574.
44. Wermuth PJ, Buchberg AM. Meis1-mediated apoptosis is caspase dependent and can be suppressed by coexpression of HoxA9 in mu- rine and human cell lines. Blood. 2005;105:1222-1230.
45. Sauvageau G, Lansdorp PM, Eaves CJ, et al. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc Natl Acad Sci USA. 1994;91:12223-12227.
46. Lawrence HJ, Sauvageau G, Ahmadi N, et al. Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells. Exp Hematol. 1995;23:1160- 1166.
47. Pineault N, Helgason CD, Lawrence HJ, Humphries RK. Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. Exp Hema-tol. 2002;30:49-57.
48. Izon DJ, Rozenfeld S, Fong ST, Komuves L, Largman C, Lawrence HJ. Loss of function of the homeobox gene Hoxa-9 perturbs early T-cell development and induces apoptosis in primitive thy- mocytes. Blood. 1998;92:383-393.
49. Lawrence HJ, Helgason CD, Sauvageau G, et al. Mice bearing a targeted interruption of the ho- meobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. Blood. 1997;89:1922-1930.
50. Lawrence HJ, Christensen J, Fong S, etal. Loss of expression oftheHoxa-9 homeoboxgeneimpairs the proliferation and repopulating ability of hemato- poietic stem cells. Blood. 2005;106:3988-3994.
51. So CW, Karsunky H, Wong P, Weissman IL, Cleary ML. Leukemic transformation of hemato- poietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood. 2004;103: 3192-3199.
52. Levis M, Tse KF, Smith BD, Garrett E, Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001;98:885-887.
53. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL: validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173-183.
54. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006;38:500-501.
55. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge- based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA.2005;102:15545-15550.
56. Moffat J, Grueneberg DA, Yang X, et al. A lentivi-ral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124:1283-1298.
57. Bridge AJ, Pebernard S, Ducraux A, NicoulazAL Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet. 2003;34:263-264.
58. Cullen BR. Enhancing and confirming the specificity of RNAi experiments. Nat Methods. 2006;3:677-681.
59. Wang J, Iwasaki H, KrivtsovA, et al. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J. 2005;24:368-381.
60. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004;104:3679-3687.
61. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
62. Giampaolo A, Felli N, Diverio D, et al. Expression pattern of HOXB6 homeobox gene in my- elomonocytic differentiation and acute myeloid leukemia. Leukemia. 2002;16:1293-1301.
63. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. Gefitinib induces my- eloid differentiation of acute myeloid leukemia. Blood. 2005;106:2841-2848.
64. Stegmaier K, Ross KN, Colavito SA, O'Malley S, Stockwell BR, Golub TR. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nat Genet. 2004;36:257-263.
65. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929-1935.
66. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709-717.